DELPHARM SAINT REMY in the news

Delpharm invested 37 million euros in a new aseptic filling line at its Saint-Rémy-sur-Avre site to boost injectable vial production capacity.

Expansion of the Saint-Rémy-sur-Avre facility with a 37 million euro investment to double production capacity and hire 60 technicians.

Delpharm exceeded 1 billion euros in revenue in 2023 and is investing heavily in injectable production capacities across its European and North American plants.

Delpharm's Saint-Remy-sur-Avre site marks a successful year of manufacturing Pfizer-BioNTech Covid-19 vaccines.

European regulators approved Delpharm and Catalent sites to significantly increase the production of Pfizer and Moderna COVID-19 vaccines.

Delpharm Saint-Rémy-sur-Avre is hiring production staff to meet growing demand for Pfizer-BioNTech COVID-19 vaccines.

European Union production facilities are scaling up to provide enough COVID-19 vaccines for 70% of adults by mid-July.

The EU projects sufficient COVID-19 vaccine doses for 70% of its adult population by mid-July, thanks to ramped-up internal production, while a French pharmaceutical subcontractor fills Pfizer/BioNTech vaccine vials.

French President Emmanuel Macron visited the Saint-Rémy-sur-Avre facility to mark the ramp-up of COVID-19 vaccine production and bottling.

President Emmanuel Macron visited the Saint-Rémy-sur-Avre facility to praise the rapid scale-up of Pfizer-BioNTech vaccine production and promote domestic pharmaceutical manufacturing.

DELPHARM SAINT REMY's factory in Eure-et-Loir has been adapted and received Messenger RNA substance to produce millions of COVID-19 vaccine doses for France and Europe, with a 18 million euros investment and creating sixty jobs.

Delpharm is investing 18 million euros and hiring 50 staff at its Saint-Rémy-sur-Avre facility to manufacture Pfizer/BioNtech COVID-19 vaccines starting April 2021.

Delpharm is manufacturing the BioNTech COVID-19 vaccine at its Saint-Rémy-sur-Avre plant, starting in April, creating 40-60 new jobs.

Delpharm Saint-Rémy is investing 18 million euros and hiring up to 60 employees to produce Pfizer-BioNTech COVID-19 vaccines.

Delpharm Saint-Rémy-sur-Avre is manufacturing the Pfizer and BioNTech COVID-19 vaccine, boosting local pharmaceutical production and employment.

Delpharm is manufacturing tens of millions of Pfizer/BioNTech COVID-19 vaccine doses at its Saint-Rémy-sur-Avre plant.

Delpharm is investing approximately 18 million euros and hiring up to 60 people to produce the Pfizer-BioNTech Covid-19 vaccine at its Saint-Rémy-sur-Avre facility.

The Delpharm site in Saint-Rémy-sur-Avre is a focus of local attention, with residents expressing both hopes for job creation and skepticism regarding COVID-19 vaccine production.

Delpharm's acquired Famar sites in L'Aigle and St-Rémy-sur-Avre are experiencing increased activity, investment, and hiring, though salary negotiations are difficult.

Delpharm is acquiring five Famar production sites, including the Saint-Rémy-sur-Avre plant, to expand its pharmaceutical contract manufacturing capacity.